A drug used to treat type 2 diabetes has been recommended for use in triple therapies for those unable to use the current method. Exenatide is currently administered once a week as a long acting medication.
This guidance suggests that for those with a BMI over 35 or patients unable to use insulin Exenatide could be used with a combination of other drugs. It could then be prescribed as a triple treatment option.
For more on this story click here